• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Roche

Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

We have the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye diseases. Our pipeline includes innovative treatments across different modalities, such as antibodies, and gene and cell therapies targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions such as thyroid eye disease and uveitic macular edema.

Contact Details:
Name: Eileen Hu, Cindy Yu
Email: eileen.hu@roche.com, cindy.yu.cy2@roche.com

Sliver

Abstract submission deadline extended

Important dates
Good News! Abstract Submission Now Open Until 21 February 2026